DOPAMINE HYDROCHLORIDE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Dopamine Hydrochloride, and what generic alternatives are available?
Dopamine Hydrochloride is a drug marketed by Abbott, Abraxis Pharm, Am Regent, Baxter Hlthcare, Hikma Intl Pharms, Hospira, Igi Labs Inc, Intl Medication, Lyphomed, Smith And Nephew, Teligent, Teva Parenteral, Warner Chilcott, and B Braun. and is included in thirty-six NDAs.
The generic ingredient in DOPAMINE HYDROCHLORIDE is dopamine hydrochloride. There are nine drug master file entries for this compound. Seven suppliers are listed for this compound. Additional details are available on the dopamine hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Dopamine Hydrochloride
A generic version of DOPAMINE HYDROCHLORIDE was approved as dopamine hydrochloride by HOSPIRA on February 4th, 1982.
Summary for DOPAMINE HYDROCHLORIDE
US Patents: | 0 |
Applicants: | 14 |
NDAs: | 36 |
Finished Product Suppliers / Packagers: | 6 |
Raw Ingredient (Bulk) Api Vendors: | 160 |
Clinical Trials: | 996 |
Patent Applications: | 2,049 |
Formulation / Manufacturing: | see details |
What excipients (inactive ingredients) are in DOPAMINE HYDROCHLORIDE? | DOPAMINE HYDROCHLORIDE excipients list |
DailyMed Link: | DOPAMINE HYDROCHLORIDE at DailyMed |
Recent Clinical Trials for DOPAMINE HYDROCHLORIDE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Dr. Ulrike Grittner | N/A |
Virginia Commonwealth University | Phase 2 |
Prof. Dr. Soyoung Q Park | N/A |
Pharmacology for DOPAMINE HYDROCHLORIDE
Drug Class | Catecholamine |